Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355306 | 0.88 | L3MBTL1 (0.74) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6357294 | 0.84 | L3MBTL1 (0.55) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6355484 | 0.83 | L3MBTL1 (0.56) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6358813 | 0.82 | MT-CO2 (0.65) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL28295486 | 0.82 | L3MBTL1 (0.64) | L3MBTL1LMNAHPGDGAAALDH1A1 | |
| SCHEMBL6357846 | 0.81 | SGMS2 (0.61) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6356912 | 0.81 | CHRNB2 (0.59) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6356702 | 0.81 | MAPK8 (0.57) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6361006 | 0.79 | L3MBTL1 (0.58) | L3MBTL1TMEM97SIGMAR1LMNAHPGD | |
| SCHEMBL6355939 | 0.79 | MT-CO2 (0.53) | L3MBTL1TMEM97SIGMAR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | L3MBTL1 2120/4885TMEM97 427/4885SIGMAR1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.